Tenderwize
Zurück zur Suche

Open-house rebate agreement for testosterone injection solution

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 432 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Testosteron in der Darreichungsform Injektionslösung, ATC G03BA03

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The notice repeatedly states that the arrangement is an open-house model and not a normal procurement procedure, which...

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for pharmaceutical products concerning testosterone in injection solution form, ATC G03BA03.
  • Open-house model with identical, non-negotiable contract terms for all qualifying pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement by AOK Bayern for testosterone injection solution (ATC G03BA03), not a competitive award procedure in the usual sense. The buyer states that it will conclude identical, non-exclusive rebate agreements with all interested pharmaceutical companies that meet the stated suitability requirement. Contracting is possible from 2026-01-01 until 2027-11-03, with contracts ending on 2027-12-31. Submission is via DTVP electronic portal with qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents need German translation.

Risiken

The notice repeatedly states that the arrangement is an open-house model and not a normal procurement procedure, which...

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for testosterone injection solution

Single lot covering non-exclusive open-house rebate agreements for the medicinal product testosterone in injection solution form, ATC G03BA03. The notice says the contract terms are fixed and not individually negotiable. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Dec 2025 - Dec 2027

Kategorie

Pharmaceutical products

Frist

Deadline Nov 03, 2027

Vergabedetails

Veröffentlichungsdatum
16 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
759950-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30